Acrivon Therapeutics to Highlight its ACR-368 OncoSignature
Introduction
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced that two […]
Content
Insert content here…
Effect on Me
Insert content here…
Effect on the World
Insert content here…
Conclusion
Insert content here…
